Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.